Anixa Biosciences (NASDAQ:ANIX) Issues Earnings Results

Anixa Biosciences (NASDAQ:ANIX) issued its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10), Zacks reports.

Anixa Biosciences Stock Up 1.1 %

Shares of NASDAQ:ANIX traded up $0.03 during trading on Tuesday, reaching $2.66. The stock had a trading volume of 42,995 shares, compared to its average volume of 102,146. The stock has a fifty day simple moving average of $2.78 and a two-hundred day simple moving average of $3.03. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.20. The firm has a market capitalization of $85.64 million, a price-to-earnings ratio of -6.82 and a beta of 0.86.

Insider Buying and Selling

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Kumar purchased 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average cost of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 75,289 shares of company stock valued at $177,021. Company insiders own 25.30% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, February 18th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, January 22nd.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.